Does Treatment Intensity Matter in Superficial Bladder Cancer?
Affiliations of authors: Health Services, Effectiveness and Outcomes Research Program, Division of Medical Oncology, Department of Medicine, Duke University School of Medicine and the Duke Comprehensive Cancer Center, Durham, NC (GHL, NMK); Duke Center for Clinical Health Policy Research, Durham, NC (GHL); Department of Surgery, Durham VA Medical Center, Durham, NC (SJF); Division of Urologic Surgery, Duke Prostate Center, Departments of Surgery and Pathology, Duke University Medical Center, Durham, NC (SJF) Correspondence to: Gary H. Lyman, MD, MPH, FRCP (Edin), Duke University School of Medicine and the Duke Comprehensive Cancer Center, 2424 Erwin Rd, Ste 205, Durham, NC 27705 (e-mail: gary.lyman{at}duke.edu’ + u + ‘@’ + d + ”//–>). The majority of patients who are diagnosed with bladder cancer initially present with noninvasive disease (1). Nevertheless, 40%–80% of patients diagnosed with superficial bladder cancers will experience a recurrence, including 10%–25% of those with pot
